Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
1. Aurinia's Q1 earnings were 16 cents, exceeding the expected 10 cents. 2. LUPKYNIS sales rose by 25% to $60 million year over year. 3. Operating income increased to $21.85 million, reversing last year's loss. 4. Fiscal 2025 revenue guidance reaffirms $250-$260 million, slightly below consensus. 5. Stock is up 2.29% to $8.18 after strong earnings report.